Literature DB >> 19735529

Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse.

H-C Diener1, D W Dodick, P J Goadsby, M E Bigal, G Bussone, S D Silberstein, N Mathew, S Ascher, J Morein, J F Hulihan, D M Biondi, S J Greenberg.   

Abstract

Chronic migraine has been linked to the excessive use of acute headache medications. Medication overuse (MO) is commonly considered the most significant risk factor for the progression of migraine from an episodic to a chronic condition. Managing MO is a challenge. Discontinuation of the acute medication can result in withdrawal headache, nausea, vomiting and sleep disturbances. This review summarizes the results from two similarly designed, randomized, placebo-controlled, multicentre studies of chronic migraine conducted in the USA and European Union. Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO. These studies may have important implications for the future of chronic migraine management, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735529     DOI: 10.1111/j.1468-2982.2009.01859.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  42 in total

1.  [Botulinum toxin type A for preventive treatment of chronic migraines].

Authors:  H Göbel; A Heinze
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 2.  Management of headache in the elderly.

Authors:  Matthew S Robbins; Richard B Lipton
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 3.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

4.  [Botulinum toxin type A in the prophylactic treatment of chronic migraine].

Authors:  H Göbel; A Heinze
Journal:  Schmerz       Date:  2011-09       Impact factor: 1.107

Review 5.  Sinus venous stenosis, intracranial hypertension and progression of primary headaches.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Pasquale Persico; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 6.  Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression?

Authors:  Roberto De Simone; Angelo Ranieri; Chiara Fiorillo; Leonilda Bilo; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2010-02-25       Impact factor: 3.307

7.  Sinus venous stenosis-associated idiopathic intracranial hypertension without papilledema as a powerful risk factor for progression and refractoriness of headache.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Vincenzo Bonavita
Journal:  Curr Pain Headache Rep       Date:  2012-06

8.  Treatment of PTSD and Chronic Daily Headache.

Authors:  Todd A Smitherman; Anna Katherine Black; Christal N Davis
Journal:  Curr Treat Options Neurol       Date:  2014-10       Impact factor: 3.598

Review 9.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 10.  Treatment of the Patient with Refractory Headache.

Authors:  Alessandro S Zagami
Journal:  Curr Pain Headache Rep       Date:  2018-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.